Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
High vs Low Intensity Neoadjuvant CRT in Rectal Cancer
NCT01064999Phase 3Unknown
- Sponsor
- Fudan University
- Start
- Mar 2010
- Primary completion
- Mar 2012
- Modality
- DNA Intercalators/Alkylators, Irreversible Covalent Inhibitors, RNA-Targeting Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of oxaliplatin, capecitabine in rectal cancer, sponsored by Fudan University. Status: unknown.
02
Drugs
oxaliplatincapecitabine
03
Conditions
rectal cancer
Beyond the preview
Go deeper on NCT01064999.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01064999.